Status
Conditions
Treatments
About
A multi-center, prospective, randomized, open-label, adaptive group sequential designed, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS
Full description
The LATE-MT trial aims to determine that compared with standard medical care without MT, performing MT in a time window that exceeds 24 hours after last seen well, is superior on the functional outcome in AIS patients due to LVO who have been carefully selected by clinical and imaging criteria. The secondary aims include comparing with standard medical care without MT, to determine whether performing MT exceeding 24 hours of last known well is safe on the risks of any ICH, sICH, and any SAE. Other secondary aims include early improvement in neurological recovery as measured by NIHSS scores at 7 days; successful recanalization rate; imaging measurements of infarct size at 24-48 hours; death or major disability (mRS 3-6); separately on death and disability (mRS 3-5); HRQoL using Euro-QoL EQ-5D questionnaire; utility-weighted modified Rankin scale scores; duration of hospitalization; residence; and hospital service costs.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Clinical Exclusion Criteria
Neuroimaging Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
382 participants in 2 patient groups
Loading...
Central trial contact
Lily Song, PhD; Craig Anderson, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal